Completed PHASE3 INTERVENTIONAL 3-arm NCT00092391

A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)

A Study of M-M-R(TM) II at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age

Sponsor: Merck Sharp & Dohme LLC

Conditions Measles Mumps Rubella Varicella

Interventions Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)

Updated 7 times since 2017 Last updated: Oct 22, 2015 Started: Feb 28, 1999 Primary completion: Jul 31, 2001 Completion: Jul 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Measles and Mumps and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 7 recorded versions since 1999 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jun 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Jun 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Feb 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.